Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.840
+0.090 (1.89%)
Nov 5, 2024, 4:00 PM EST - Market closed
Elicio Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 3.43 | 12.89 | 6.16 | 9.28 | 14.97 | 6.81 |
Cash & Short-Term Investments | 3.43 | 12.89 | 6.16 | 9.28 | 14.97 | 6.81 |
Cash Growth | -84.20% | 109.45% | -33.65% | -38.01% | 119.78% | - |
Prepaid Expenses | 2.6 | 2.43 | 2.27 | 0.18 | 0.17 | 0.38 |
Restricted Cash | 0.4 | 0.72 | 1.64 | 0.15 | 0.15 | - |
Other Current Assets | 0.18 | 0.3 | 0.65 | 0.76 | 0.17 | 0.06 |
Total Current Assets | 6.69 | 16.35 | 10.72 | 10.36 | 15.45 | 7.25 |
Property, Plant & Equipment | 6.74 | 7.28 | 8.5 | 0.89 | 1.02 | 1.43 |
Other Long-Term Assets | 2.32 | 3.52 | 3.45 | 3.57 | 3.18 | 0.16 |
Total Assets | 15.75 | 27.15 | 22.66 | 14.81 | 19.66 | 8.84 |
Accounts Payable | 1.06 | 4.37 | 2.81 | 1.68 | 1.65 | 0.53 |
Accrued Expenses | 4.32 | 3.76 | 1.94 | 2.32 | 1.22 | 0.79 |
Short-Term Debt | - | - | - | 11.8 | - | - |
Current Portion of Leases | 0.85 | 0.91 | 0.69 | - | 0.44 | 0.43 |
Other Current Liabilities | 1.36 | 0.73 | 1.44 | 3.09 | - | - |
Total Current Liabilities | 7.59 | 9.77 | 6.87 | 18.88 | 3.31 | 1.75 |
Long-Term Leases | 5.57 | 6.01 | 6.79 | - | - | 0.44 |
Other Long-Term Liabilities | 4.25 | - | 0.09 | 0.03 | - | - |
Total Liabilities | 17.4 | 15.77 | 13.75 | 18.91 | 3.31 | 2.19 |
Common Stock | 0.1 | 0.1 | 0 | 0.17 | 0.13 | 0.04 |
Additional Paid-In Capital | 159.89 | 153.83 | 4.86 | 4.09 | 3.34 | 1.75 |
Retained Earnings | -161.26 | -142.2 | -107.01 | -78.8 | -52.4 | -36.69 |
Treasury Stock | -0.15 | -0.15 | - | - | - | - |
Comprehensive Income & Other | -0.24 | -0.2 | - | - | -0.21 | - |
Total Common Equity | -1.65 | 11.37 | -102.15 | -74.54 | -49.14 | -34.9 |
Shareholders' Equity | -1.65 | 11.37 | 8.92 | -4.1 | 16.35 | 6.65 |
Total Liabilities & Equity | 15.75 | 27.15 | 22.66 | 14.81 | 19.66 | 8.84 |
Total Debt | 6.42 | 6.92 | 7.48 | 11.8 | 0.44 | 0.87 |
Net Cash (Debt) | -2.99 | 5.98 | -1.33 | -2.52 | 14.53 | 5.94 |
Net Cash Growth | - | - | - | - | 144.47% | - |
Net Cash Per Share | -0.31 | 1.18 | -4.19 | -0.16 | 1.35 | 1.51 |
Filing Date Shares Outstanding | 10.76 | 10.22 | 17.7 | 17.14 | 13.06 | 3.94 |
Total Common Shares Outstanding | 10.26 | 9.6 | 17.7 | 17.14 | 13.06 | 3.94 |
Working Capital | -0.9 | 6.58 | 3.85 | -8.52 | 12.15 | 5.51 |
Book Value Per Share | -0.16 | 1.18 | -5.77 | -4.35 | -3.76 | -8.85 |
Tangible Book Value | -1.65 | 11.37 | -102.15 | -74.54 | -49.14 | -34.9 |
Tangible Book Value Per Share | -0.16 | 1.18 | -5.77 | -4.35 | -3.76 | -8.85 |
Machinery | 1.86 | 1.82 | 2.15 | - | 1.12 | 0.92 |
Leasehold Improvements | 0.13 | 0.13 | 0.12 | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.